5-Amino-1MQ // The NNMT Blocker
A small-molecule NNMT inhibitor that attacks fat at the enzymatic level. By blocking nicotinamide N-methyltransferase, 5-Amino-1MQ increases intracellular NAD+, shrinks existing adipocytes, and may convert white fat to metabolically active brown fat. Oral dosing, unique mechanism, zero overlap with GLP-1 or GH pathways.
A completely different target.
5-Amino-1MQ operates in a different universe from GLP-1 agonists and GH fragments. It targets NNMT — an enzyme overexpressed in obese fat tissue that depletes NAD+ and SAM, putting a brake on fat cell metabolism. Remove the brake, and the cells start burning again.
Oral. Simple. No injection.
One of the simplest dosing protocols in fat loss. Oral capsule, once or twice daily. No reconstitution, no refrigeration, no injection timing.
A novel target with strong preclinical support.
NNMT is an established target in metabolic disease research. Preclinical studies show inhibiting this enzyme reduces fat cell size, increases metabolic rate, and prevents diet-induced obesity in animal models. The mechanism is elegant: NNMT depletes two critical cofactors (NAD+ and SAM) in fat cells, and blocking it restores both.
Human clinical data is still early, but the animal data is compelling and the mechanism well-understood. What makes 5-Amino-1MQ valuable is that it targets a completely unique pathway with no overlap to GLP-1, GIP, glucagon, GH, or monoamine systems. It's a true complement to any other fat loss compound.
How it stacks against the competition.
| Compound | Receptors | Weight Loss | Half-Life | FDA Status |
|---|---|---|---|---|
| 5-Amino-1MQ | NNMT Inhibitor | Mild-Moderate | Not characterized | Research |
| AOD-9604 | GH Fragment | Moderate | ~30 min | TGA-Approved (AU) |
| Fragment 176-191 | GH Fragment | Moderate | ~30 min | Research |
| Tesofensine | Monoamine RI | ~12.8% | ~9 days | Phase 3 |
| Semaglutide | GLP-1 | ~15–17% | ~7 days | FDA Approved |
What to watch for.
5-Amino-1MQ's side effect profile requires careful monitoring. Relatively new compound with limited long-term data, but community reports are consistently favorable.
- Mild GI discomfort in some users
- Limited long-term human safety data
- Theoretical effects on sleep/energy via NAD+
- Generally well-tolerated in community data
- Monitor liver enzymes (hepatic metabolism)
- No cardiovascular or hormonal effects reported
- Standard metabolic panel (CMP)
- Liver enzymes (ALT, AST)
- Lipid panel
- Fasting glucose and insulin
- General metabolic surveillance
- Best synergy with Fragment 176-191 or AOD-9604
- Complementary with GLP-1 agonists (unique NNMT mechanism)
- Pairs with Tesofensine (monoamine + NNMT = dual independent)
- Oral dosing = easiest compound to add to any protocol
- No known contraindications with other peptides
- Works in any stack because it hits a unique target
- Room temperature (oral capsule)
- Protect from moisture
- No reconstitution needed
- Small molecule — ensure pharma-grade synthesis
- MW 173.21 Da — verify on COA
- No cold chain required
Compounds that complement 5-Amino-1MQ.
5-Amino-1MQ's unique NNMT/NAD+ mechanism means it pairs cleanly with every other fat loss pathway. Zero overlap makes it the easiest add to any stack.
The easiest add to any fat loss protocol.
5-Amino-1MQ's value is simplicity and uniqueness. Oral, targets a pathway no other compound touches (NNMT/NAD+), no known contraindications. The limitation is data maturity — human evidence is early. But mechanism is sound, target validated, risk profile low. If building a multi-compound fat loss stack, this is the first addition — layers in with zero overlap. Pair with Fragment 176-191 for a clean, non-GLP-1 protocol.
Our free 50-page Protocol Guide includes the complete Metabolic Fat Loss Stack with 5-Amino-1MQ — titration schedules, stacking recommendations, blood work panels, and tracking templates.